MARIELLA DISTURCO
NEW YORK, NY NPI 1306208764
Browse related groups: NY Astellas Pharma US Inc All categories
General Payments — all program years on this page
$888.14
- Category: General Payments
- Program years: PY2021–2024
- Record count: 35
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $321.47 across 9 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $198.99 | 2 |
| Food and Beverage | $122.48 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $252.16 | 5 |
| Sage Therapeutics, Inc. | $18.59 | 1 |
| Organon LLC | $17.69 | 1 |
| Exeltis, USA Inc. | $17.06 | 1 |
| Evofem Biosciences, Inc. | $15.97 | 1 |
By program year
Records — PY2024 (9)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1091282464 | Evofem Biosciences, Inc. | $15.97 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120390041 | Sage Therapeutics, Inc. | $18.59 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1136237376 | Organon Llc | $17.69 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1140286847 | Astellas Pharma US Inc | $14.78 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1140287499 | Astellas Pharma US Inc | $19.78 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1140287545 | Astellas Pharma US Inc | $99.99 | 09/23/2024 | Education | Undisputed | 01/23/2026 | View at CMS |
| 1140287563 | Astellas Pharma US Inc | $99.00 | 09/23/2024 | Education | Undisputed | 01/23/2026 | View at CMS |
| 1140288005 | Astellas Pharma US Inc | $18.61 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1149991895 | Exeltis, USA Inc. | $17.06 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.